- Home
- GOSS vs ONL Comparison
GOSS vs ONL Comparison
Compare GOSS & ONL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- ONL
- Stock Information
- Founded
- GOSS 2015
- ONL 2021
- Country
- GOSS United States
- ONL United States
- Employees
- GOSS N/A
- ONL N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- ONL Real Estate Investment Trusts
- Sector
- GOSS Health Care
- ONL Real Estate
- Exchange
- GOSS Nasdaq
- ONL Nasdaq
- Market Cap
- GOSS 212.8M
- ONL 223.5M
- IPO Year
- GOSS 2019
- ONL N/A
- Fundamental
- Price
- GOSS $1.40
- ONL $4.03
- Analyst Decision
- GOSS Strong Buy
- ONL Hold
- Analyst Count
- GOSS 5
- ONL 1
- Target Price
- GOSS $9.20
- ONL N/A
- AVG Volume (30 Days)
- GOSS 1.6M
- ONL 227.4K
- Earning Date
- GOSS 03-04-2025
- ONL 03-05-2025
- Dividend Yield
- GOSS N/A
- ONL 9.93%
- EPS Growth
- GOSS N/A
- ONL N/A
- EPS
- GOSS N/A
- ONL N/A
- Revenue
- GOSS $105,322,000.00
- ONL $169,644,000.00
- Revenue This Year
- GOSS N/A
- ONL N/A
- Revenue Next Year
- GOSS N/A
- ONL N/A
- P/E Ratio
- GOSS N/A
- ONL N/A
- Revenue Growth
- GOSS N/A
- ONL N/A
- 52 Week Low
- GOSS $0.50
- ONL $3.01
- 52 Week High
- GOSS $1.60
- ONL $4.51
- Technical
- Relative Strength Index (RSI)
- GOSS 67.09
- ONL 51.12
- Support Level
- GOSS $1.37
- ONL $3.96
- Resistance Level
- GOSS $1.55
- ONL $4.15
- Average True Range (ATR)
- GOSS 0.13
- ONL 0.10
- MACD
- GOSS 0.03
- ONL -0.00
- Stochastic Oscillator
- GOSS 75.81
- ONL 36.84
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About ONL Orion Office REIT Inc.
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.